Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious adverse events such as pancytopenia. Today, data about pancytopenia are scarce. The objective was to investigate reports of pancytopenia adverse events related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib and pamiparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.
Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of pancytopenia related to PARPi.
Study Type
OBSERVATIONAL
Enrollment
200
All patients treated at least with 1 PARPi
Alexandre Joachim
Caen, Basse Normandie, France
Pancytopenia reports related to PARPi.
Identification of the pancytopenia adverse event related to PARP inhibitors reported in the World Health Organization's (WHO) database of individual safety case reports.
Time frame: From inception to Feb, 2021
Description of the latency period since first PARPi exposure.
Time frame: From inception to Feb, 2021
Description of the fatality rate.
Time frame: From inception to Feb, 2021
Description of patients who experienced co-reported adverse events
Time frame: From inception to Feb, 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.